CU23337B7 - Resolución de sal quiral - Google Patents
Resolución de sal quiralInfo
- Publication number
- CU23337B7 CU23337B7 CU20030229A CU20030229A CU23337B7 CU 23337 B7 CU23337 B7 CU 23337B7 CU 20030229 A CU20030229 A CU 20030229A CU 20030229 A CU20030229 A CU 20030229A CU 23337 B7 CU23337 B7 CU 23337B7
- Authority
- CU
- Cuba
- Prior art keywords
- enantiomers
- compound
- solution
- quiral
- resolution
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002244 precipitate Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 230000000707 stereoselective effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29477501P | 2001-05-31 | 2001-05-31 | |
| US34104801P | 2001-12-06 | 2001-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23337B7 true CU23337B7 (es) | 2009-01-20 |
Family
ID=26968730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20030229A CU23337B7 (es) | 2001-05-31 | 2003-10-13 | Resolución de sal quiral |
Country Status (52)
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| PT1382339E (pt) * | 1999-12-10 | 2008-02-06 | Pfizer Prod Inc | Composições que contêm derivados de pirrolo[2,3-d]- pirimidina |
| ES2257410T3 (es) * | 2000-06-26 | 2006-08-01 | Pfizer Products Inc. | Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores. |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
| ATE402700T1 (de) * | 2002-08-27 | 2008-08-15 | Merck Patent Gmbh | Glycinamid-derivate als raf-kinase-hemmer |
| KR20050086784A (ko) | 2002-11-26 | 2005-08-30 | 화이자 프로덕츠 인크. | 이식 거부반응의 치료 방법 |
| AU2004265288A1 (en) | 2003-07-30 | 2005-02-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| JP2007536310A (ja) * | 2004-05-03 | 2007-12-13 | ノバルティス アクチエンゲゼルシャフト | Ｓ１ｐ受容体アゴニストおよびｊａｋ３キナーゼ阻害剤を含む、組合せ剤 |
| WO2006004703A2 (en) | 2004-06-29 | 2006-01-12 | Amgen Inc. | PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY |
| JP2008508358A (ja) | 2004-08-02 | 2008-03-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物 |
| MX2007006204A (es) * | 2004-11-24 | 2007-06-20 | Novartis Ag | Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa. |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| US8163767B2 (en) | 2005-07-14 | 2012-04-24 | Astellas Pharma Inc. | Heterocyclic Janus Kinase 3 inhibitors |
| BRPI0613876A2 (pt) | 2005-07-29 | 2011-02-15 | Pfizer Prod Inc | derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese |
| US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
| SI3184526T1 (sl) | 2005-12-13 | 2019-03-29 | Incyte Holdings Corporation | Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze |
| CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| EP2121692B1 (en) | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| MX2009013402A (es) | 2007-06-13 | 2010-02-24 | Incyte Corp | Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo. |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| NZ582188A (en) * | 2007-07-11 | 2012-03-30 | Pfizer | Pharmaceutical compositions and methods of treating dry eye disorders |
| LT2265607T (lt) | 2008-02-15 | 2017-03-27 | Rigel Pharmaceuticals, Inc. | Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių |
| CN102026999B (zh) | 2008-03-11 | 2014-03-05 | 因塞特公司 | 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物 |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
| EP2271631B1 (en) | 2008-04-22 | 2018-07-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| BRPI0916931A2 (pt) * | 2008-08-01 | 2015-11-24 | Biocryst Pharm Inc | agentes terapêuticos |
| HRP20140395T1 (hr) | 2008-08-20 | 2014-06-06 | Zoetis Llc | SPOJEVI PIROLO[2,3-d]PIRIMIDINA |
| WO2010093808A1 (en) * | 2009-02-11 | 2010-08-19 | Reaction Biology Corp. | Selective kinase inhibitors |
| EP2421867B1 (en) * | 2009-04-20 | 2015-09-02 | Auspex Pharmaceuticals, Llc | Piperidine inhibitors of janus kinase 3 |
| WO2010135650A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| WO2010135621A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CN102596962A (zh) * | 2009-09-10 | 2012-07-18 | 弗·哈夫曼-拉罗切有限公司 | Jak抑制剂 |
| MX2012004180A (es) | 2009-10-09 | 2012-07-17 | Incyte Corp | Derivados de hidroxil, ceto y glucuronido de 3-(4-7h-pirrolo[2,3-d ]pirimidin-a-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo. |
| CN102574860A (zh) | 2009-10-15 | 2012-07-11 | 辉瑞大药厂 | 吡咯并[2,3-d]嘧啶化合物 |
| EP2513114B1 (en) | 2009-12-18 | 2014-04-02 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| WO2011086053A1 (en) * | 2010-01-12 | 2011-07-21 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| CA2788071A1 (en) | 2010-02-05 | 2011-08-11 | Pfizer Inc. | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
| PE20130038A1 (es) | 2010-03-10 | 2013-01-28 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de jak1 |
| SG10201503983QA (en) | 2010-05-21 | 2015-06-29 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
| WO2012061428A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
| EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| EP2481397A1 (en) | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Pharmaceutical compositions comprising tasocitinib |
| EP2481411A1 (en) | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib |
| CA2827673C (en) | 2011-02-18 | 2020-10-27 | Novartis Pharma Ag | Mtor/jak inhibitor combination therapy |
| EP2691395B1 (en) | 2011-03-28 | 2017-08-30 | ratiopharm GmbH | Processes for preparing tofacitinib salts |
| US9050342B2 (en) | 2011-03-29 | 2015-06-09 | Pfizer Inc. | Beneficial effects of combination therapy on cholesterol |
| AU2012241018B2 (en) * | 2011-04-08 | 2015-11-12 | Pfizer Inc. | Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer |
| EP2524688B1 (en) | 2011-05-11 | 2013-05-01 | ratiopharm GmbH | Composition for modified release comprising ranolazine |
| EP2721028B1 (en) | 2011-06-20 | 2015-11-04 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| WO2013023119A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | JAK P13K/mTOR COMBINATION THERAPY |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| JP6039683B2 (ja) | 2011-11-23 | 2016-12-07 | ポートラ ファーマシューティカルズ， インコーポレイテッド | ピラジンキナーゼ阻害剤 |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| MX2014006479A (es) | 2011-11-30 | 2015-01-22 | Univ Emory | Inhibidores antivirales de la janus cinasa utiles en el tratamiento o prevencion de infecciones retrovirales y otras infecciones virales. |
| EP3170826A1 (en) | 2011-12-15 | 2017-05-24 | ratiopharm GmbH | Tofacitinib mono-malate salt |
| AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
| CN104837817B (zh) | 2012-07-25 | 2017-03-22 | 力奇制药公司 | 制备3‑氨基‑哌啶化合物的合成路线 |
| US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| PL2919766T3 (pl) | 2012-11-15 | 2021-10-04 | Incyte Holdings Corporation | Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu |
| CN104955803B (zh) * | 2012-11-30 | 2017-11-28 | 斯洛文尼亚莱柯制药股份有限公司 | 通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物 |
| US9481679B2 (en) | 2012-12-17 | 2016-11-01 | Sun Pharmaceutical Industries Limited | Process for the preparation of tofacitinib and intermediates thereof |
| US9670160B2 (en) | 2012-12-28 | 2017-06-06 | Glenmark Pharmaceuticals Limited | Process for the preparation of tofacitinib and intermediates thereof |
| PE20151764A1 (es) | 2013-02-22 | 2015-12-03 | Pfizer | Derivados de pirrolo[2,3-d]pirimidina |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| WO2014174073A1 (en) | 2013-04-26 | 2014-10-30 | Sandoz Ag | Sustained release formulations of tofacitinib |
| LT3030227T (lt) | 2013-08-07 | 2020-06-10 | Incyte Corporation | Prailginto atpalaidavimo jak1 inhibitoriaus dozavimo formos |
| CN104513248B (zh) * | 2013-09-30 | 2019-05-24 | 重庆医药工业研究院有限责任公司 | 一种托法替尼中间体的纯化方法 |
| EP3318565B1 (en) | 2013-12-05 | 2021-04-14 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| PL3539965T3 (pl) * | 2013-12-09 | 2021-07-05 | Unichem Laboratories Limited | Ulepszony sposób wytwarzania (3r,4r)-(1-benzylo-4-mety-lopiperydyn-3-ylo)metyloaminy |
| CA2881262A1 (en) | 2014-02-06 | 2015-08-06 | Prabhudas Bodhuri | Solid forms of tofacitinib salts |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| ES2750655T3 (es) | 2014-08-12 | 2020-03-26 | Pfizer | Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa |
| US10617690B2 (en) | 2015-01-20 | 2020-04-14 | Wuxi Fortune Pharmaceutical Co., Ltd | JAK inhibitor |
| KR101791119B1 (ko) | 2015-02-17 | 2017-11-20 | (주)아모레퍼시픽 | N-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법 |
| CN104761556B (zh) * | 2015-03-21 | 2017-06-23 | 河北国龙制药有限公司 | 托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法 |
| EP3078665A1 (en) | 2015-04-10 | 2016-10-12 | OLON S.p.A. | Efficient method for the preparation of tofacitinib citrate |
| EA036058B1 (ru) | 2015-04-29 | 2020-09-21 | Уси Форчун Фармасьютикал Ко., Лтд | Ингибитор jak |
| ES2928757T3 (es) | 2015-05-01 | 2022-11-22 | Pfizer | Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa |
| DK3305788T3 (da) | 2015-05-29 | 2020-09-28 | Wuxi Fortune Pharmaceutical Co Ltd | Janus-kinase-hæmmer |
| WO2017017542A1 (en) * | 2015-07-27 | 2017-02-02 | Unichem Laboratories Limited | Tofacitinib orally disintegrating tablets |
| KR101771219B1 (ko) * | 2015-08-21 | 2017-09-05 | 양지화학 주식회사 | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 |
| US10045981B2 (en) | 2015-11-24 | 2018-08-14 | Jakpharm, Llc | Selective kinase inhibitors |
| CN105348287A (zh) * | 2015-11-30 | 2016-02-24 | 宁波立华制药有限公司 | 一种枸橼酸托法替布的新型合成工艺 |
| KR102565407B1 (ko) * | 2016-01-04 | 2023-08-10 | (주)아모레퍼시픽 | 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법 |
| US20190083609A1 (en) | 2016-01-18 | 2019-03-21 | Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) | Tofacitinib as vaccination immune modulator |
| WO2018004306A1 (en) | 2016-06-30 | 2018-01-04 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| CN106831538B (zh) * | 2017-01-22 | 2019-06-25 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
| KR102398659B1 (ko) | 2017-03-17 | 2022-05-16 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 피롤로트리아진 유도체 |
| CN107602569A (zh) * | 2017-10-23 | 2018-01-19 | 上海博悦生物科技有限公司 | 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途 |
| KR102078805B1 (ko) | 2017-11-30 | 2020-02-19 | 보령제약 주식회사 | 토파시티닙을 포함하는 약제학적 조성물 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| KR102577242B1 (ko) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| SI3733673T1 (sl) | 2017-12-28 | 2022-09-30 | Daewoong Pharmaceutical Co., Ltd. | Oksi-fluoropiperidinski derivat kot kinazni inhibitor |
| KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| MX2020007973A (es) | 2018-01-30 | 2020-12-07 | Incyte Corp | Procesos para preparar (1-(3-fluoro-2-(trifluorometil)isonicotinil )piperidin-4-ona). |
| CA3089108A1 (en) * | 2018-01-31 | 2019-08-08 | Twi Pharmaceuticals, Inc. | Topical formulations comprising tofacitinib |
| US12161748B2 (en) | 2018-01-31 | 2024-12-10 | Twi Biotechnology, Inc. | Topical formulations comprising tofacitinib |
| SI3773593T1 (sl) | 2018-03-30 | 2024-08-30 | Incyte Corporation | Zdravljenje hidradenitisa suppurative z zaviralci jak |
| KR102131107B1 (ko) * | 2019-01-15 | 2020-07-07 | 주식회사 다산제약 | 3-아미노-피페리딘 화합물의 신규한 제조 방법 |
| NL2022471B1 (en) | 2019-01-29 | 2020-08-18 | Vationpharma B V | Solid state forms of oclacitinib |
| US12364696B2 (en) | 2019-02-27 | 2025-07-22 | Jak Slave Pty Ltd | Treatment of autoimmune disease |
| US12269830B2 (en) | 2019-03-13 | 2025-04-08 | Intas Pharmaceuticals Ltd. | Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof |
| WO2020198583A1 (en) | 2019-03-27 | 2020-10-01 | Insilico Medicine Ip Limited | Bicyclic jak inhibitors and uses thereof |
| WO2020204647A1 (en) * | 2019-04-05 | 2020-10-08 | Yuhan Corporation | Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same |
| MX2022005882A (es) | 2019-11-14 | 2022-06-14 | Pfizer | Combinaciones de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2- il)metoxi)-7-metoxiisoquinolin-6-carboxamida y formas de dosis orales. |
| EP4067354B1 (en) | 2019-11-25 | 2025-10-22 | Daewoong Pharmaceutical Co., Ltd. | Novel triazolopyridine derivative and pharmaceutical composition comprising same |
| WO2021198980A1 (en) | 2020-04-04 | 2021-10-07 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US20240166651A1 (en) * | 2021-03-15 | 2024-05-23 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
| CN113549075B (zh) * | 2021-06-23 | 2025-09-23 | 合肥华方医药科技有限公司 | 一种枸橼酸托法替布非对映异构体杂质的合成方法 |
| EP4180042A1 (en) | 2021-11-15 | 2023-05-17 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A film coated tablet comprising micronized tofacitinib |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8403224A (nl) * | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| US6136595A (en) * | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
| US5389509A (en) * | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| EP0682027B1 (de) | 1994-05-03 | 1997-10-15 | Novartis AG | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| JPH07330732A (ja) * | 1994-06-10 | 1995-12-19 | Kyorin Pharmaceut Co Ltd | 光学活性な３−アミノ−１−ベンジルピペリジン誘導体 |
| US6136596A (en) * | 1995-05-19 | 2000-10-24 | University Of Massachusetts | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
| MX9709867A (es) | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos. |
| US6066638A (en) | 1995-07-05 | 2000-05-23 | E. I. Du Pont De Nemours And Company | Fungicidal pyrimidinones |
| ES2172670T3 (es) | 1995-07-06 | 2002-10-01 | Novartis Ag | Pirrolpirimidinas y procedimientos para su preparacion. |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| US5965563A (en) | 1995-11-14 | 1999-10-12 | Pharmacia & Upjohn S.P.A. | Aryl and heteroaryl purine compounds |
| PT888349E (pt) | 1996-01-23 | 2002-10-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| AU1794697A (en) | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| CA2260058A1 (en) | 1996-07-13 | 1998-01-22 | Kathryn Jane Smith | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| JP4242928B2 (ja) * | 1996-08-23 | 2009-03-25 | ノバルティス アクチエンゲゼルシャフト | 置換ピロロピリミジンおよびその製造方法 |
| AU4718997A (en) | 1996-11-27 | 1998-06-22 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
| ATE391719T1 (de) | 1997-02-05 | 2008-04-15 | Warner Lambert Co | Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation |
| US6187552B1 (en) * | 1997-03-24 | 2001-02-13 | Pharmacia & Upjohn Company | Method for identifying inhibitors of JAK2/cytokine receptor binding |
| AU3378799A (en) | 1998-04-02 | 1999-10-25 | Neurogen Corporation | Aminoalkyl substituted pyrrolo(2,3-b)pyridine and pyrrolo(2,3-d)pyrimidine derivatives: modulators of crf1 receptors |
| EP1082311A1 (en) | 1998-05-28 | 2001-03-14 | Parker Hughes Institute | Quinazolines for treating brain tumor |
| TW505646B (en) * | 1998-06-19 | 2002-10-11 | Pfizer Prod Inc | Pyrrolo [2,3-d] pyrimidine compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| EP1091739A1 (en) | 1998-06-30 | 2001-04-18 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
| MXPA01001893A (es) | 1998-08-21 | 2002-04-24 | Parker Hughes Inst | Derivados de quinazolina. |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| PT1382339E (pt) * | 1999-12-10 | 2008-02-06 | Pfizer Prod Inc | Composições que contêm derivados de pirrolo[2,3-d]- pirimidina |
| ES2257410T3 (es) | 2000-06-26 | 2006-08-01 | Pfizer Products Inc. | Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores. |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| WO2006004703A2 (en) * | 2004-06-29 | 2006-01-12 | Amgen Inc. | PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY |
-
2002
- 2002-05-23 US US10/154,699 patent/US7301023B2/en not_active Expired - Lifetime
- 2002-05-29 CA CA002448281A patent/CA2448281C/en not_active Expired - Lifetime
- 2002-05-29 NZ NZ540332A patent/NZ540332A/en not_active IP Right Cessation
- 2002-05-29 EP EP05015454.1A patent/EP1666481B9/en not_active Expired - Lifetime
- 2002-05-29 GE GE5361A patent/GEP20063784B/en unknown
- 2002-05-29 EE EEP200300594A patent/EE05332B1/xx active Protection Beyond IP Right Term
- 2002-05-29 HR HR20030943A patent/HRP20030943B1/xx not_active IP Right Cessation
- 2002-05-29 UA UA20031110841A patent/UA80093C2/uk unknown
- 2002-05-29 CN CNA028108175A patent/CN1729192A/zh active Pending
- 2002-05-29 EP EP05015461A patent/EP1609781B1/en not_active Expired - Lifetime
- 2002-05-29 KR KR1020067025590A patent/KR20060133117A/ko not_active Ceased
- 2002-05-29 PL PL02367945A patent/PL367945A1/xx unknown
- 2002-05-29 SK SK1465-2003A patent/SK288199B6/sk unknown
- 2002-05-29 EA EA200600575A patent/EA012666B1/ru active Protection Beyond IP Right Term
- 2002-05-29 KR KR10-2003-7015681A patent/KR20040003037A/ko not_active Ceased
- 2002-05-29 ES ES05015461T patent/ES2369226T3/es not_active Expired - Lifetime
- 2002-05-29 KR KR1020067001821A patent/KR100869409B1/ko not_active Expired - Lifetime
- 2002-05-29 BR BR0209246-8A patent/BR0209246A/pt not_active Application Discontinuation
- 2002-05-29 KR KR1020077025832A patent/KR100868814B1/ko not_active Expired - Lifetime
- 2002-05-29 EA EA200301193A patent/EA007251B1/ru active Protection Beyond IP Right Term
- 2002-05-29 TW TW091111480A patent/TWI310384B/zh active
- 2002-05-29 DK DK05015454.1T patent/DK1666481T3/da active
- 2002-05-29 HU HUP0400152A patent/HU230876B1/hu active Protection Beyond IP Right Term
- 2002-05-29 AU AU2002304401A patent/AU2002304401C1/en not_active Expired
- 2002-05-29 ES ES05015454T patent/ES2393385T3/es not_active Expired - Lifetime
- 2002-05-29 TW TW092133699A patent/TWI316061B/zh not_active IP Right Cessation
- 2002-05-29 KR KR1020087018519A patent/KR100926875B1/ko not_active Expired - Lifetime
- 2002-05-29 TN TNPCT/IB2002/001905A patent/TNSN03128A1/fr unknown
- 2002-05-29 RS YU92303A patent/RS52144B/sr unknown
- 2002-05-29 CZ CZ2003-3260A patent/CZ304366B6/cs not_active IP Right Cessation
- 2002-05-29 SI SI200231004T patent/SI1666481T1/sl unknown
- 2002-05-29 OA OA1200300308A patent/OA12612A/en unknown
- 2002-05-29 NZ NZ530380A patent/NZ530380A/en not_active IP Right Cessation
- 2002-05-29 EP EP02733058A patent/EP1392694A1/en not_active Withdrawn
- 2002-05-29 PT PT50154541T patent/PT1666481E/pt unknown
- 2002-05-29 AT AT05015461T patent/ATE519741T1/de not_active IP Right Cessation
- 2002-05-29 PL PL409305A patent/PL228155B1/pl unknown
- 2002-05-29 WO PCT/IB2002/001905 patent/WO2002096909A1/en not_active Ceased
- 2002-05-29 SK SK50033-2011A patent/SK288192B6/sk active Protection Beyond IP Right Term
- 2002-05-29 IL IL15858802A patent/IL158588A0/xx active IP Right Grant
- 2002-05-29 PE PE2002000452A patent/PE20030561A1/es not_active Application Discontinuation
- 2002-05-29 JP JP2003500088A patent/JP4381137B2/ja not_active Expired - Lifetime
- 2002-05-29 MX MXPA03011062A patent/MXPA03011062A/es active IP Right Grant
- 2002-05-30 GT GT200200100AK patent/GT200200100AA/es unknown
- 2002-05-30 UY UY27317A patent/UY27317A1/es not_active Application Discontinuation
- 2002-05-30 AR ARP020102017A patent/AR037321A1/es not_active Application Discontinuation
- 2002-05-30 GT GT200200100A patent/GT200200100A/es unknown
- 2002-05-30 MY MYPI20021988A patent/MY129649A/en unknown
- 2002-05-30 PA PA20028546301A patent/PA8546301A1/es unknown
- 2002-05-31 AP APAP/P/2002/002550A patent/AP1859A/en active
-
2003
- 2003-10-13 IS IS6993A patent/IS3023B/is unknown
- 2003-10-13 CU CU20030229A patent/CU23337B7/es not_active IP Right Cessation
- 2003-10-14 ZA ZA200307982A patent/ZA200307982B/en unknown
- 2003-11-21 MA MA27410A patent/MA27029A1/fr unknown
- 2003-11-24 NO NO20035201A patent/NO328578B1/no not_active IP Right Cessation
- 2003-11-26 EC EC2003004865A patent/ECSP034865A/es unknown
- 2003-11-27 BG BG108389A patent/BG66489B1/bg unknown
-
2004
- 2004-05-07 AR ARP040101561A patent/AR045680A2/es unknown
- 2004-06-16 US US10/869,101 patent/US7432370B2/en not_active Expired - Lifetime
-
2008
- 2008-03-14 CL CL200800762A patent/CL2008000762A1/es unknown
- 2008-07-16 AU AU2008203170A patent/AU2008203170B2/en active Active
- 2008-07-24 CR CR10177A patent/CR10177A/es unknown
-
2009
- 2009-10-13 NO NO20093135A patent/NO20093135L/no not_active Application Discontinuation
-
2012
- 2012-11-09 CY CY20121101069T patent/CY1113322T1/el unknown
-
2017
- 2017-08-02 NL NL300887C patent/NL300887I2/nl unknown
- 2017-08-08 LT LTPA2017025C patent/LTC1666481I2/lt unknown
- 2017-08-09 LU LU00031C patent/LUC00031I2/fr unknown
- 2017-08-17 BE BE2017C032C patent/BE2017C032I2/fr unknown
- 2017-09-01 CY CY2017028C patent/CY2017028I1/el unknown
- 2017-09-04 FR FR17C1031C patent/FR17C1031I2/fr active Active
- 2017-09-08 NO NO2017047C patent/NO2017047I1/no unknown
-
2019
- 2019-02-19 HU HUS1900008C patent/HUS1900008I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23337B7 (es) | Resolución de sal quiral | |
| BRPI0516911A (pt) | método para a preparação de um composto e composto de anilina | |
| EA200500203A1 (ru) | Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| MXPA04003007A (es) | Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades. | |
| BRPI0411268C8 (pt) | Processo para a preparação de compostos 3-aril butil-amina substituído | |
| CY1112406T1 (el) | Διενυδρη υδροχλωρικη (s)-(-)-1-(4-φθοροϊσοκινολιν-5-υλ)σουλφονυλ-2-μεθυλ-1,4-ομοπιπεραζινη | |
| ECSP056071A (es) | Nueva difenilazetidinona con características fisiológicas mejoradas, correspondiente método de producción, medicamentos que contienen dicho compuesto y su uso | |
| BR0317005A (pt) | Processo para a preparação de compostos ativos opticamente puros | |
| SV2004001555A (es) | Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos | |
| BRPI0518647A2 (pt) | processo para a produÇço de um composto, e, composto | |
| TNSN04250A1 (en) | Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof. | |
| BRPI0416534A (pt) | composições multiparticuladas com estabilidade melhorada | |
| DK1756052T3 (da) | Forbedret fremgangsmåde til at fremstille 3-hydroxy-4-hydroxymethyl-pyrrolidin-forbindelser | |
| EA200400487A1 (ru) | Фармацевтическая композиция длительного высвобождения, содержащая метформин | |
| BRPI0411308A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
| MXPA04008926A (es) | Inhibidores de entrada a moleculas pequenas. | |
| BRPI0409069A (pt) | compostos quìmicos | |
| BRPI0412447A (pt) | método para a preparação de mirtazapina enantiomericamente pura, e, método para a seleção de um ácido ou uma combinação ácido/solvente apropriada para uma reação de fechamento de anel estereoespecìfica de composto enantiomericamente puro | |
| EA200300458A1 (ru) | Новые соединения аминотриазолона, способ их получения и фармацевтические композиции, содержащие их | |
| EA200600760A1 (ru) | Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их | |
| ES2074532T3 (es) | Procedimiento para la preparacion de 4-(ciclico-amido)-2h-1-benzopiranos y 4-amino-3-hidroxi-2h-1-benzopiranos. | |
| PE20010165A1 (es) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano como antagonistas de la sustancia p | |
| DE602004006021D1 (de) | Verfahren zur racematspaltung von nefopam | |
| AR111318A1 (es) | Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse (for not paying fees) |